Ultragenyx Reports First Quarter 2017 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ultragenyx Pharma (RARE) PT Raised to $68 at Jefferies; Reiterates Hold
May 8, 2017 7:29 AM EDTJefferies raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $68.00 (from $66.00) while maintaining a Hold rating. 1Q expenses consisted of $51.3M R&D vs. $48.0M estimates, and $18.7M G&A vs. $20.2M.
Following recently reported ph.III KRN23 results in adult... More
Ultragenyx Pharma (RARE) Tops Q1 EPS by 8c
May 4, 2017 4:46 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.63), $0.08 better than the analyst estimate of ($1.71).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More